The invention described herein provides a fast dispersing oral solid dosage form containing monoamine oxidase B inhibitor (MAO-B inhibitor) as the active ingredient, and method of treating disease therewith, such as Parkinson's disease. In one embodiment, the monoamine oxidase B inhibitor selegiline or its analog can be the sole active ingredient in the composition administered. The dosage form composition is formulated to promote absorption through the buccal, sublingual, pharyngeal and/or esophageal mucous membrane tissue, such that at least 5% of the active ingredient is absorbed within one minute of placement in the oral cavity, as determined by a buccal absorption test. Monoamine oxidase B inhibitor compounds administered in accordance with the invention decrease the amount of undesirable metabolites associated with first pass effect of selegiline, for example, such as amphetamine and methamphetamine. The invention provides a number of other advantages over conventional orally administered tablet forms, including administration of monoamine oxidase B inhibitor compounds to patients that have difficulty swallowing.

Brewer; Francesca Mary

Johnson; Edward Stewart

Clarke; Anthony

R.P. Scherer Technologies, LLC

Pharmaceutical composition formulated for pre-gastric absorption of monoamine oxidase B inhibitors

Compositions are provided to immobilize and protect oxidase enzymes from proteolytic and hydrolytic attack, utilizing a porous, inert organic, or inorganic, substrate matrix useful in generating hydrogen peroxide in situ for use in oral, topical mucosal and intracavity uses for use in or on the human body and other mammalian, reptile, fish and amphibians. The selected porosity of the support matrix provides the basis for generating hydrogen peroxide on a steady state basis. Both diatomaceous earth and silica gel, either in natural or pre-silanized forms, allow for the excluding of non-preferred enzymes from the support matrix, and for diffusion of the peroxide in the reduction of oral pathogens and their attendant malodorous compounds, or other pathogens in the mucosa, bodily fluids and cavities, in addition to oxidizing color bodies to affect bleaching.

Pugliese; Peter T.

Pugliese; Steven M.

Ehrhard; Joseph A.

Immobilized glucose oxidase for use in oral hygiene

A glucose sensor assembly useful in patient systems includes an oxygen sensor from which glucose levels in the vicinity of the peritoneal cavity may be inferred. The sensor assembly may be associated with electronics, such as any or all of a DC power supply, an LED source of blue light, a photoreceptor for red light, a CPU, and transceiver, by a direct percutaneous connection. Alternatively they may be associated transdermally with the sensor and some of the electronics being located subdurally. Insulin infusion means are contemplated to respond manually or mechanically to information from the sensors through the CPU. Mechanical response may be automatic. Infusion means may be located subdurally. It is contemplated that the present invention enable revitalization or replacement of fluorescing compounds and glucose oxidase within the sensor assembly.

Sorenson Medical, Inc.

System, apparatus and method for inferring glucose levels within the peritoneum with implantable sensors

oxidase

càries dental

dental caries

oxidase/càries dental

Pharmaceutical composition formulated for pre-gastric absorption of monoamine oxidase B inhibitors

Immobilized glucose oxidase for use in oral hygiene

System, apparatus and method for inferring glucose levels within the peritoneum with implantable sensors

La base de dades d’herbes medicinals més completa avalada per la ciència